Fertility Focus

Fertility Focus, rebranded as viO HealthTech in 2022, is a medical technology company specializing in women's reproductive health. The company was established in 2005 to commercialize intellectual property from Bristol University related to predicting ovulation by monitoring core body temperature. The business is led by CEO Robert Milnes, who has over two decades of experience in women's health.

The company’s core offering is the OvuSense™ platform, a subscription-based service featuring a vaginal sensor (OvuCore™) that measures core body temperature overnight. This data, analyzed by the OvuSense app, predicts ovulation up to 24 hours in advance and confirms the exact date of ovulation with 99% accuracy in real-time. The platform is designed to assist women, particularly those with irregular cycles or conditions like Polycystic Ovary Syndrome (PCOS), who are trying to conceive. The company also offers the OvuFirst™, a skin-worn sensor for women who want a less invasive method to track their cycles.

For clinicians, viO HealthTech provides OvuSense® Pro, a portal that allows healthcare professionals to remotely access a patient's cycle data. This feature helps in diagnosing ovulatory issues, timing medical tests, and monitoring the effectiveness of treatments. The business model is direct-to-consumer, with products sold globally online. The company has received funding from investors including Foresight Group, Coutts Investment Club, Midven, and Norgenix.

Keywords: fertility monitoring, ovulation prediction, core body temperature, OvuSense, viO HealthTech, reproductive health, femtech, medical device, trying to conceive, PCOS, digital therapeutics, OvuCore, fertility tracking, cycle analysis, women's health technology, ovulation sensor, fertility diagnosis, remote health monitoring, personalized health, CE marked medical device